Clinical trials: Non-small Cell Lung Cancer Metastatic
Non-Small-Cell Lung Carcinoma
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.
- Trial name
- NCT00112346
- Testing
- Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
- Where
- 38 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Non-small Cell Lung Cancer
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free survival will be the primary outcome. Subjects will need to have Epidermal Growth Factor Receptor (EGFR) wild-type, locally advance or…
- Trial name
- HER3-Lung (NCT02134015)
- Testing
- Patritumab, Erlotinib
- Where
- 98 sites in United States, Belgium and 8 more
- Volunteers
- 145 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
- Trial name
- NCT06082635
- Testing
- TGRX-326, Crizotinib
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Lung Cancer
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006215
- Testing
- filgrastim, docetaxel, vinorelbine tartrate
- Where
- 19 sites in United States
- Sponsor
- Amgen
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer
A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, demcizumab (OMP-21M18), when given in combination with carboplatin and pemetrexed, a standard drug treatment regimen for non-squamous…
- Trial name
- NCT01189968
- Testing
- Demcizumab
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in…
- Conditions
- Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
- Trial name
- NCT03892096
- Testing
- Blood-based cell-free cfDNA qPCR assay
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Cadex Genomics
Carcinoma, Non-Squamous Non-Small-Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
- Trial name
- NCT00152477
- Testing
- Carboplatin, Paclitaxel, CDP791 10mg/kg
- Where
- 21 sites in Hungary, Poland and 1 more
- Volunteers
- 165 people
- Sponsor
- UCB Pharma
Metastatic Non-small Cell Lung Cancer
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC
AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Trial name
- NCT02330367
- Testing
- AC0010
- Where
- 17 sites in China
- Volunteers
- 368 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
- Trial name
- NCT00092001
- Testing
- Sunitinib
- Where
- 14 sites in United States, Italy and 1 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1…
- Trial name
- swalloWTail (NCT06532032)
- Testing
- Amivantamab, Docetaxel
- Where
- 15 sites in United States, Taiwan and 2 more
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT06448312
- Testing
- SKB264, Pembrolizumab
- Where
- 64 sites in China
- Volunteers
- 406 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with…
- Trial name
- NCT07824882
- Testing
- HS-20093 for Injection, Adebrelimab Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hansoh BioMedical R&D Company
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma
A Phase 2 Clinical Study of ABSK061 and ABSK043
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
- Conditions
- HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
- Trial name
- NCT06632262
- Testing
- ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
- Where
- 21 sites in China
- Volunteers
- 202 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Non-Small Cell Lung Cancer
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
The goal of this Phase 1 clinical trial is to learn whether KAN-001, an investigational live biotherapeutic product, can be safely given with pembrolizumab, with or without chemotherapy, to adults with PD-L1-positive, inoperable…
- Trial name
- NCT07910942
- Testing
- KAN-001, Pembrolizumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Kanvas Biosciences
Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed.
- Trial name
- BROADWAY (NCT02066103)
- Testing
- Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mercator MedSystems, Inc.
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.